🇺🇸 Daratumumab/rHuPH20 in United States

17 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pyrexia — 3 reports (17.65%)
  2. Asthenia — 2 reports (11.76%)
  3. Dehydration — 2 reports (11.76%)
  4. Lymphopenia — 2 reports (11.76%)
  5. Myalgia — 2 reports (11.76%)
  6. Nausea — 2 reports (11.76%)
  7. Abdominal Pain — 1 report (5.88%)
  8. Diarrhoea — 1 report (5.88%)
  9. Eructation — 1 report (5.88%)
  10. Erythema — 1 report (5.88%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Daratumumab/rHuPH20 approved in United States?

Daratumumab/rHuPH20 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Daratumumab/rHuPH20 in United States?

Masonic Cancer Center, University of Minnesota is the originator. The local marketing authorisation holder may differ — check the official source linked above.